Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00967005 · ClinicalTrials.gov registry record · Phase 2
N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers
A Phase 2 study of Tobacco Use Disorder and Gambling, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 2
- Study locations
NCT00967005 is a Phase 2 study of Tobacco Use Disorder and Gambling that has completed, run by University of Chicago. The registered enrollment target is 28 participants, below the 239-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (88% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00967005, a Phase 2 study of Tobacco Use Disorder and Gambling, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 2
- Study locations
Study Summary
The objective of this application is to examine whether, given its mechanism of action, the dietary supplement, N-acetyl cysteine (NAC) will reduce both tobacco use and pathological gamblers (PG) symptoms in nicotine dependent pathological gamblers.
Conditions Studied
Interventions
- DRUG N Acetyl Cysteine
- OTHER Sugar Pill
Study Locations (2)
Connecticut
- Yale University School of Medicine - New Haven
Minnesota
- University of Minnesota School of Medicine - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2009-09 |
| Est. Completion | 2014-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00967005
The ClinicalTrials.gov registry entry for NCT00967005 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 239-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (88% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Tobacco Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which N Acetyl Cysteine is the first listed.
NCT00967005 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Connecticut, Minnesota.
Frequently Asked Questions
What is clinical trial NCT00967005 about?
NCT00967005 is a clinical study titled "N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers". The objective of this application is to examine whether, given its mechanism of action, the dietary supplement, N-acetyl cysteine (NAC) will reduce both tobacco use and pathological gamblers (PG) symptoms in nicotine dependent pathological gamblers.
What is the current status of trial NCT00967005?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2009-09. Estimated completion is 2014-08.
What conditions does trial NCT00967005 study?
This clinical trial studies the following conditions: Tobacco Use Disorder, Gambling.
What interventions are being tested in trial NCT00967005?
The interventions under investigation include: N Acetyl Cysteine (DRUG), Sugar Pill (OTHER).
Who is sponsoring clinical trial NCT00967005?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00967005 being conducted?
This trial has 2 study locations across Connecticut, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tobacco Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nicotine Regulation for Dual Users of E-cigarettes and Cigarettes
RECRUITING · Phase 2
-
Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity
RECRUITING · Phase 2
-
Cannabidiol for Reducing Cigarette Use
RECRUITING · Phase 2
-
An fMRI Study of the Effects of Clavulanic Acid on Drug Addiction
RECRUITING · Phase 2
-
Neuroimaging Correlates and Feasibility of Transcranial Magnetic Stimulation (TMS) to Improve Smoking Cessation Outcomes in Veterans With Comorbid PTSD
RECRUITING · Phase 2
-
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 2
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.